BOZEN, Sud-Tirol, Italy, July 20, 2010 /PRNewswire/ -- Health Robotics today announced that it recently signed agreements to grant exclusive CytoCare distribution rights in Spain and Portugal to world-leading IV Therapy company Grifols S.A., and to install the first-ever Cancer Therapy Robot in Spain at Vall d'Hebron University Hospital in Barcelona in November 2010.
We are very excited to have been selected by Health Robotics as their long-term exclusive CytoCare partner in Spain and Portugal, adding the Cancer Therapy Robot in our core Iberian peninsula market to our prior i.v.STATION distribution rights. CytoCare, the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures, represents an ideal complement to our other market-leading Pharmacy Automation products. Vall d'Hebron University Hospital has demonstrated a long trajectory of innovation, utilizing new technologies to achieve excellent peer-reviewed and published efficiency and medication safety results, with prestigious awards such as Best European Pharmacy Management, ESADE's Management Innovation, and finally the Best Health Care Ideas in 2009, stated Xavier Guix, Vice President of Marketing for Grifols' Hospital System Division.
It is very exciting to expand our i.v.STATION relationship at such a prestigious hospital as Vall d'Hebron University Hospital, with its world-renowned cancer research program and the well-documented scientific publications by Dr. Josep Monterde and his team of scientists and pharmacists; we feel rewarded with this new contract after 1.000 Bed Bolzano General Hospital hosted an inspection team from Vall d'Hebron University Hospital in order to ascertain CytoCare's speed, flexibility, and safety in comparison with other IV Robotics companies, and demonstrating that CytoCare handled 70% of Chemo IV doses within a 4 hour time-window. Additionally, Grifols is the perfect fit for CytoCare in Spain and Portugal due to its well-established distribution channels, commitment to patient safety, its company stability and superior market footprint, and finally its world-class service infrastructure. In addition to the obvious success in expanding our partnership with Grifols and receiving a repeat endorsement from an existing Health Robotics' partner, I'm very pleased that this new contract symbolizes the first CytoCare installation in Spain, and the eight European Union member country to embrace CytoCare for its Oncology Therapy Compounding needs, stated Werner Rainer, Health Robotics' CEO.
About Vall d'Hebron University Hospital:
Vall d'Hebron University Hospital, the leading hospital complex in Catalonia and one of the largest in Spain, is comprised of four large centers - the General Area, the Maternity and Children's Area, the Traumatology and Rehabilitation Area and the Outpatient Surgery Unit (Pere Virgili Health Care Park) - which cover almost all the medical and surgical specialties. The Vall d'Hebron University Hospital, with a total of more than 1400 beds, also house various teaching centers, public health care enterprises, research centers, laboratories and other complementary facilities. http://www.vhebron.net/
About Grifols S.A.:
Grifols International is a Spain-based company engaged in the healthcare sector and is listed on Ibex-35 stock market. Grifols is involved in the research, development, manufacturing and marketing of plasma derivates, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Founded in 1940, Grifols currently operates in 90 countries with more than 6.000 employees, 26 subsidiaries with combined gross revenues over EUR800 million, and a EUR3 billion market capitalization. For more information, please visit http://www.grifols.com
About Health Robotics:
Health Robotics is the undisputed global leading supplier of life-critical intra-venous medication robots, providing healthcare facilities in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs], i.v.SOFT(TM) [workflow engine for manual compounding], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug-exchange errors, decrease other therapy oversights and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff.
For more company information including a corporate video, please visit http://www.health-robotics.com/en/about-health-robotics/. For additional information, please contact:
Health Robotics S.r.l. Claudia Flaim, Marketing Coordinator Phone: +39-0471-200-372 firstname.lastname@example.org
SOURCE: Health Robotics
CONTACT: Health Robotics S.r.l., Claudia Flaim, Marketing Coordinator,Phone: +39-0471-200-372, email@example.com